Orencia approved for polyarticular juvenile idiopathic arthritis

Orencia (abatacept) is now licensed for use in children aged 6 years and older in combination with methotrexate for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) where there has been an insufficient response to other DMARDs including methotrexate.

The safety and efficacy of Orencia have not been evaluated in children under 6 years of age and, therefore, it is not licensed in this age range.

View Orencia drug record

Further information: BMS

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Macrolide prescribing in pregnancy linked to risk of birth defects

Macrolide prescribing in pregnancy linked to risk of birth defects

Researchers have called for caution when prescribing...

NICE overturns advice to increase steroid dose in children with asthma

NICE overturns advice to increase steroid dose in children with asthma

NICE has withdrawn its recommendation to quadruple...

New antibiotic guidance for leg ulcer infection

New antibiotic guidance for leg ulcer infection

NICE has issued guidance on antibiotic choices and...